A Prospective Randomized Placebo-Controlled Double-Blinded Pilot Study of Misoprostol Rectal Suppositories in the Prevention of Acute and Chronic Radiation Proctitis Symptoms in Prostate Cancer Patients

Khan, Amber M.; Birk, John W.; Anderson, Joseph C.; Georgsson, Maria; Park, Tae L.; Smith, Candace J.; Comer, Gail M.
August 2000
American Journal of Gastroenterology;Aug2000, Vol. 95 Issue 8, p1961
Academic Journal
OBJECTIVE: Radiation proctitis is a known complication of radiation therapy for prostate cancer. Available medical treatment is usually ineffective and has focused on relieving symptoms after damage has occurred. Our study aimed at evaluating the use of misoprostol rectal suppositories in the prevention of acute as well as chronic radiation proctitis symptoms. METHODS: A prospective, randomized, placebo-controlled. double-blinded trial was conducted in patients with recently diagnosed stages B and C prostate cancer who underwent external beam irradiation. Patients received either a misoprostol or a placebo suppository 1 h before each radiation session. Misoprostol suppositories were made from two 200-µ-g tablets (Cytotec, Searle Pharmaceuticals. Skokie, IL), whereas the placebo was made from cocoa butter. A 12-point radiation proctitis symptom score was obtained from each patient at 4, 8, 12, and 36 wk after radiation therapy. RESULTS: A total of 16 patients were enrolled. Seven patients received placebo, and nine patients received misoprostol. Mean radiation proctitis symptom scores in the placebo group were 4.86, 5.86, 5.71, and 3.83 at 4, 8, 12, and 36 wk, respectively. The mean scores in the misoprostol group were 0.78, 0.67, 0.33, and 0.37 at 4, 8, 12, and 36 wk, respectively. The difference between the two groups was statistically significant (p < 0.05) at 4, 8, 12, and 36 wk. CONCLUSION: Misoprostol rectal suppositories significantly reduce acute and chronic radiation proctitis symptoms in patients receiving radiation therapy for prostate cancer.


Related Articles

  • Suppository tip. R.M.D. // Cortlandt Forum;6/25/96, Vol. 9 Issue 6, p101 

    Offers an advice for administering rectal suppositories. Insertion of the suppository's blunt end first; Function of the rectal sphincter in the retention of the suppository.

  • PROVENGE EXTENDS SURVIVAL IN PATIENTS WITH PROSTATE CANCER.  // Biotech Business;Dec2005, Vol. 18 Issue 12, p2 

    Discusses the results of a study conducted by Dendreon Corp. on 2005 concerning its PROVENGE immunotherapy for the treatment of prostate cancer. Comparison between patients who received PROVENGE and placebo; Occurrence of prostate cancer in the U.S.; Information on Dendreon.

  • Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223. Mukherji, Deborah; Dika, Imane El; Temraz, Sally; Haidar, Mohammed; Shamseddine, Ali // Therapeutics & Clinical Risk Management;2014, Vol. 10, p373 

    Radium-223 is a first-in-class alpha particle-emitting radiopharmaceutical approved for the treatment of bone metastatic castration-resistant prostate cancer. Radium-223 is administered intravenously with no requirement for complex shielding and specifically targets areas of bone metastasis. In...

  • Miscellaneous Notes.  // Formulary;Aug2001, Vol. 36 Issue 8, p556 

    Reports on the reintroduction of the drug Canasa or mesalamine rectal suppositories, by Axcan Scandipharm, in the United States market. Use of drug for treating active ulcerative proctitis; Availability of the drug in tablet and capsule formulations; Recommended dosage; Average wholesale price.

  • Seeds of hope.  // Men's Health (10544836);Jul/Aug95, Vol. 10 Issue 6, p96 

    Reports on the effectiveness of a new option for treating prostate cancer, in which a rice-sized radioactive seed is placed directly in the prostate gland. Safety of the outpatient technique.

  • Long-term study becomes benchmark for XRT. Overmyer, Mac // Urology Times;Dec95, Vol. 23 Issue 12, p1 

    Reports on a long-term study of radical prostatectomy of the Mayo Clinic which provides a benchmark for future studies in the use of external beam radiation therapy (XRT) for prostatic carcinoma. Good prognosis for men aged 60 years or younger presenting with early stage prostate cancer...

  • How low should PSA be after radiation therapy for PCa? Bankhead, Charles // Urology Times;Jul96, Vol. 24 Issue 7, p1 

    Focuses on the use of nadir for long-term recurrence-free survival after irradiation for prostate cancer. Use of a combination of radiotherapy: Threshold of PSA.

  • Low pre-Tx PSA may predict adjuvant radiation success. McBroom, Stacy // Urology Times;Mar99, Vol. 27 Issue 3, p13 

    Reports on a University of Washington, Seattle study which concluded that men who respond to adjuvant radiation therapy for locally recurrent prostate cancer tend to have lower pre-radiation PSA levels and a longer time to biochemical failure following prostatectomy than those not responding to...

  • Evolution of toxicity after conformal radiotherapy for prostate cancer. Abdalla, I; Ignacio, L; Vaida, F; Mei-Hsu; Awan, A; Jani, A; Mamo, C; Weichselbaum, R R; Vijayakumar, S // Prostate Cancer & Prostatic Diseases;2002, Vol. 5 Issue 4, p296 

    The limiting factor for radiation (RT) dose-escalation is normal tissue toxicity. In dose-escalation studies, it is important to determine the factors associated with toxicity and the length of follow-up period after which a particular RT dose is considered safe.We analyzed 449 prostate cancer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics